Bosulif 100 mg, 400 mg & 500 mg film-coated tablets
*Company:
Pfizer Healthcare Ireland Unlimited CompanyStatus:
No Recent UpdateLegal Category:
Product subject to medical prescription which may not be renewed (A)Active Ingredient(s):
*Additional information is available within the SPC or upon request to the company
Updated on 06 June 2025
File name
Adv PIL BO 25_0 tabs IE_clean.pdf
Reasons for updating
- Change to section 2 - what you need to know - warnings and precautions
- Change to section 4 - possible side effects
- Change to section 6 - date of revision
Free text change information supplied by the pharmaceutical company
The Tablet PIL has been updated to reflect the SPC changes regarding: the addition of pediatric patients to the indication and posology sections; additional of information in multiple warnings and precautions; additional warning regarding patients of Asian origin; new information on PPI’s and changes in adverse event frequency and description.
Updated on 06 June 2025
File name
Adv SPC BO 26_0 IE_clean.pdf
Reasons for updating
- Change to section 1 - Name of medicinal product
- Change to section 2 - Qualitative and quantitative composition
- Change to section 3 - Pharmaceutical form
- Change to section 4.1 - Therapeutic indications
- Change to section 4.2 - Posology and method of administration
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
- Change to section 4.8 - Undesirable effects
- Change to section 5.1 - Pharmacodynamic properties
- Change to section 5.2 - Pharmacokinetic properties
- Change to section 5.3 - Preclinical safety data
- Change to section 6.1 - List of excipients
- Change to section 6.3 - Shelf life
- Change to section 6.5 - Nature and contents of container
- Change to section 6.6 - Special precautions for disposal and other handling
- Change to section 8 - Marketing authorisation number(s)
- Change to section 10 - Date of revision of the text
Legal category:Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
The SPC for Bosulif tablets has been updated as follows:
• Extension of the indications for Bosulif (bosutinib) for the treatment of paediatric patients 1 year of age and older with chronic phase (CP) Ph+ CML, newly-diagnosed (ND) or resistant or intolerant (R/I) to prior therapy.
• Details of the new Bosulif presentation of hard capsule dosage form in 50 mg and 100 mg strengths.
• SPC sections impacted are 1, 2, 3, 4.1, 4.2, 4.4, 4.5, 4.8, 5.1, 5.2, 5.3, 6.1, 6.3, 6.5, 6.6, 8, 10
Updated on 17 January 2025
File name
Adv SPC BO 25_0 IE_clean.pdf
Reasons for updating
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.8 - Undesirable effects
- Change to section 5.1 - Pharmacodynamic properties
Legal category:Product subject to medical prescription which may not be renewed (A)
Updated on 17 January 2025
File name
Adv PIL BO 24_0 IE_clean.pdf
Reasons for updating
- Change to section 2 - what you need to know - warnings and precautions
- Change to section 4 - possible side effects
- Change to section 6 - date of revision
Updated on 05 May 2023
File name
Adv SPC BO 24_2 IE clean.pdf
Reasons for updating
- Change to section 4.8 - Undesirable effects
- Change to section 9 - Date of first authorisation/renewal of the authorisation
- Change to section 10 - Date of revision of the text
Legal category:Product subject to medical prescription which may not be renewed (A)
Updated on 05 May 2023
File name
Adv PIL BO 23_2 IE NI clean.pdf
Reasons for updating
- Change to section 4 - possible side effects
- Change to section 6 - date of revision
Updated on 13 February 2023
File name
AdvSPCBO230IE.pdf
Reasons for updating
- Document format updated
Legal category:Product subject to medical prescription which may not be renewed (A)
Updated on 21 April 2022
File name
AdvSPCBO230IE.pdf
Reasons for updating
- Change to section 4.2 - Posology and method of administration
- Change to section 4.3 - Contraindications
- Change to section 4.8 - Undesirable effects
- Change to Section 4.8 – Undesirable effects - how to report a side effect
- Change to section 5.1 - Pharmacodynamic properties
- Removal of Black Inverted Triangle
Legal category:Product subject to medical prescription which may not be renewed (A)
Updated on 21 April 2022
File name
AdvPILBO220IENI.pdf
Reasons for updating
- Change to section 3 - duration of treatment
- Change to section 4 - possible side effects
- Change to section 4 - how to report a side effect
- Change to section 6 - date of revision
- Change to other sources of information section
- Joint PIL superseded by individual PILs
- Change of distributor details
- Removal of Black Inverted Triangle
Updated on 05 April 2022
File name
DEC202156033_Adv SPC BO 22_0 IE clean.pdf
Reasons for updating
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.8 - Undesirable effects
- Change to section 5.1 - Pharmacodynamic properties
- Change to section 9 - Date of first authorisation/renewal of the authorisation
Legal category:Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
The SPC has been updated as follows:
Section 4.4 Special warnings and precautions for use – Renal impairment This
section is updated to include data from the final clinical study reports to further
support that a clinically significant decline in renal function is recognised as a class
effect of all tyrosine kinase inhibitor(s) (TKIs) used in CML patients.
Section 4.8 Undesirable effects – entire section is updated based on final results from clinical study B18711053 - where the frequencies of several adverse events have been increased, thus leading to an upgrading and change of the frequency category for the adverse events; Drug hypersensitivity, Dizziness, Pleural effusion, Pulmonary hypertension, Pancreatitis, Hepatic enzyme increased/Hepatocellular injury, Pruritus and Erythema multiforme.
Section 5.1 Pharmacodynamic properties – Clinical efficacy This section is updated
to include the results of long-term endpoints up to 60 months where the data
continues to demonstrate superior efficacy of bosutinib (400 mg) over imatinib.
Tables detailing the the efficacy results of major molecular response (MMR) and
complete cytogenetic response (CCyR) have additionally been updated.
Section 9: DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION. Update "Date of latest renewal" to 11 February 2021
Updated on 05 April 2022
File name
DEC202156033_Adv PIL BO 21_0 IE clean.pdf
Reasons for updating
- Change to section 4 - possible side effects
- Change to section 6 - date of revision
Updated on 01 April 2022
File name
Adv SPC BO 23_0 IE.pdf
Reasons for updating
- Change to section 4.2 - Posology and method of administration
- Change to section 4.3 - Contraindications
- Change to section 4.8 - Undesirable effects
- Change to Section 4.8 – Undesirable effects - how to report a side effect
- Change to section 5.1 - Pharmacodynamic properties
- Removal of Black Inverted Triangle
Legal category:Product subject to medical prescription which may not be renewed (A)
Updated on 01 April 2022
File name
Adv SPC BO 23_0 IE.pdf
Reasons for updating
- Change to section 4.2 - Posology and method of administration
- Change to section 4.3 - Contraindications
- Change to section 4.8 - Undesirable effects
- Change to section 5.1 - Pharmacodynamic properties
- Removal of Black Inverted Triangle
Legal category:Product subject to medical prescription which may not be renewed (A)
Updated on 01 April 2022
File name
Adv PIL BO 22_0 IE NI.pdf
Reasons for updating
- Change to section 3 - duration of treatment
- Change to section 4 - possible side effects
- Change to section 4 - how to report a side effect
- Change to section 6 - date of revision
- Change to other sources of information section
- Individual PILs superseded by joint PIL
- Change of distributor details
- Removal of Black Inverted Triangle
Updated on 19 August 2021
File name
DEC202156033_Adv SPC BO 22_0 IE clean.pdf
Reasons for updating
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.8 - Undesirable effects
- Change to section 5.1 - Pharmacodynamic properties
- Change to section 9 - Date of first authorisation/renewal of the authorisation
Legal category:Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
|
The SPC has been updated as follows: Section 4.4 Special warnings and precautions for use – Renal impairment This section is updated to include data from the final clinical study reports to further support that a clinically significant decline in renal function is recognised as a class effect of all tyrosine kinase inhibitor(s) (TKIs) used in CML patients.
Section 4.8 Undesirable effects – entire section is updated based on final results from clinical study B18711053 - where the frequencies of several adverse events have been increased, thus leading to an upgrading and change of the frequency category for the adverse events; Drug hypersensitivity, Dizziness, Pleural effusion, Pulmonary hypertension, Pancreatitis, Hepatic enzyme increased/Hepatocellular injury, Pruritus and Erythema multiforme.
Section 5.1 Pharmacodynamic properties – Clinical efficacy This section is updated to include the results of long-term endpoints up to 60 months where the data continues to demonstrate superior efficacy of bosutinib (400 mg) over imatinib. Tables detailing the the efficacy results of major molecular response (MMR) and complete cytogenetic response (CCyR) have additionally been updated.
Section 9: DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION. Update "Date of latest renewal" to 11 February 2021
|
Updated on 19 August 2021
File name
DEC202156033_Adv PIL BO 21_0 IE clean.pdf
Reasons for updating
- Change to section 4 - possible side effects
- Change to section 6 - date of revision
Updated on 21 December 2020
File name
DEC202084274_Adv SPC BO 21_0 IE.pdf
Reasons for updating
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.8 - Undesirable effects
Legal category:Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
The SPC has been updated as follows:
1. ADR addition to Section 4.4:Photosensitivity
Exposure to direct sunlight or UV radiation should be avoided or minimised due to the risk of photosensitivity associated with bosutinib treatment. Patients should be instructed to use measures such as protective clothing and sunscreen with high sun protection factor (SPF)
2. Section 4.8 - The following adverse reaction photosensitivity is added under the SOC “skin and subcutaneous tissue disorders” with a frequency common: Photosensitivity reaction.
Updated on 21 December 2020
File name
DEC202084274_ADV PIL BO 20_0 IE.pdf
Reasons for updating
- Change to section 2 - what you need to know - warnings and precautions
- Change to section 4 - possible side effects
- Change to section 6 - date of revision
Updated on 15 October 2020
File name
DEC202068708_Adv SPC BO 20_0 IE.pdf
Reasons for updating
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 5.3 - Preclinical safety data
Legal category:Product subject to medical prescription which may not be renewed (A)
Updated on 15 October 2020
File name
DEC202068708_ADV PIL BO 19_0 IE.pdf
Reasons for updating
- Change to section 2 - what you need to know - contraindications
- Change to section 6 - date of revision
Updated on 24 September 2020
File name
ADV PIL BO 16_0 UK.pdf
Reasons for updating
- Change to section 4 - how to report a side effect
- Change to other sources of information section
- Removal of one or more presentations from joint PIL
Updated on 21 August 2020
File name
DEC202055404_Adv SPC BO 19_1 IE.pdf
Reasons for updating
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 5.2 - Pharmacokinetic properties
- Change to section 9 - Date of first authorisation/renewal of the authorisation
Legal category:Product subject to medical prescription which may not be renewed (A)
Updated on 27 June 2019
File name
DEC201932916_ADV PIL BO 14_0 UK IE clean.pdf
Reasons for updating
- Change to section 2 - pregnancy, breast feeding and fertility
- Change to section 6 - date of revision
Updated on 27 June 2019
File name
DEC201932916_Adv SPC BO 18_0 IE clean.pdf
Reasons for updating
- Change to section 4.6 - Pregnancy and lactation
- Change to section 5.3 - Preclinical safety data
Legal category:Product subject to medical prescription which may not be renewed (A)
Updated on 27 February 2019
File name
ADV PIL BO 13_0 UK IE clean.pdf
Reasons for updating
- Change to section 2 - pregnancy, breast feeding and fertility
- Change to section 3 - dose and frequency
- Change to section 6 - what the product looks like and pack contents
- Change to section 6 - date of revision
Updated on 27 February 2019
File name
Adv SPC BO 17_0 IE clean.pdf
Reasons for updating
- Change to section 4.2 - Posology and method of administration
- Change to section 4.8 - Undesirable effects
- Change to section 5.2 - Pharmacokinetic properties
- Change to section 6.1 - List of excipients
- Change to section 9 - Date of first authorisation/renewal of the authorisation
Legal category:Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
The SPC has been updated as follows: QRD changes to sections 4.2, 4.8, 5.2, 5.2, 6.1 and 9
Updated on 08 August 2018
File name
ADV PIL BO 12_0 UK IE clean.pdf
Reasons for updating
- Change to section 6 - marketing authorisation holder
- Change to section 6 - date of revision
Updated on 08 August 2018
File name
Adv SPC BO 16_0 IE clean.pdf
Reasons for updating
- Change to section 7 - Marketing authorisation holder
- Change to section 10 - Date of revision of the text
Legal category:Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
The SPC has been updated as follows:
Section 7 – Change to MAH
Section 10 – Date of revision of text
Updated on 29 May 2018
File name
ADV PIL BO 11_0 UK IE clean.pdf
Reasons for updating
- Change to section 2 - pregnancy, breast feeding and fertility
- Change to section 6 - what the product contains
- Change to section 6 - what the product looks like and pack contents
- Change to section 6 - manufacturer
- Change to section 6 - date of revision
- Introduction of new strength
Updated on 29 May 2018
File name
Adv_SPC_BO_15_1_IE_clean.docx
Reasons for updating
- Change to section 1 - Name of medicinal product
- Change to section 2 - Qualitative and quantitative composition
- Change to section 3 - Pharmaceutical form
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.6 - Pregnancy and lactation
- Change to section 4.8 - Undesirable effects
- Change to section 6.1 - List of excipients
- Change to section 6.5 - Nature and contents of container
- Change to section 8 - Marketing authorisation number(s)
Legal category:Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
- The SPC has been updated as follows: sections 1, 2, 3, 6.1, 6.5, 8 updated to make reference 400mg presentation and minor editorial changes to sections 4.4, 4.6 and 4.8
Updated on 22 May 2018
File name
Adv_SPC_BO_14_0_IE_clean.docx
Reasons for updating
- Change to section 4.1 - Therapeutic indications
- Change to section 4.2 - Posology and method of administration
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
- Change to section 4.6 - Pregnancy and lactation
- Change to Section 4.8 – Undesirable effects - how to report a side effect
- Change to section 5.1 - Pharmacodynamic properties
- Change to section 5.2 - Pharmacokinetic properties
- Change to section 5.3 - Preclinical safety data
- Change to section 10 - Date of revision of the text
Legal category:Product subject to medical prescription which may not be renewed (A)
Updated on 17 May 2018
File name
Adv_SPC_BO_13_0_IE_Clean.docx
Reasons for updating
- New SPC for new product
Legal category:Product subject to medical prescription which may not be renewed (A)
Updated on 11 May 2018
File name
Adv_SPC_BO_13_0_IE_Clean.docx
Reasons for updating
- New SPC for new product
Legal category:Product subject to medical prescription which may not be renewed (A)
Updated on 11 May 2018
File name
Adv_SPC_BO_13_0_IE_Clean.docx
Reasons for updating
- New SPC for new product
Legal category:Product subject to medical prescription which may not be renewed (A)
Updated on 08 May 2018
File name
Adv_SPC_BO_13_0_IE_Clean.docx
Reasons for updating
- New SPC for new product
Legal category:Product subject to medical prescription which may not be renewed (A)
Updated on 02 May 2018
File name
Adv_SPC_BO_13_0_IE_Clean.docx
Reasons for updating
- Change to section 4.1 - Therapeutic indications
- Change to section 4.2 - Posology and method of administration
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
- Change to section 4.6 - Pregnancy and lactation
- Change to section 4.8 - Undesirable effects
- Change to section 5.1 - Pharmacodynamic properties
- Change to section 5.2 - Pharmacokinetic properties
- Change to section 5.3 - Preclinical safety data
- Change to section 9 - Date of first authorisation/renewal of the authorisation
- Change to section 10 - Date of revision of the text
Legal category:Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
The SPC has been updated as follows in sections 4.1, 4.2, 4.4, 4.5, 4.6, 4.8, 5.1, 5.2, 5.3, 9 &10 for the extension of indication to: newly diagnosed chronic phase (CP) Philadelphia chromosome-positive chronic myelogenous leukaemia (Ph+ CML)
Updated on 26 April 2018
File name
ADV PIL BO 10_0 UK IE clean.pdf
Reasons for updating
- Change to section 1 - what the product is used for
- Change to section 2 - what you need to know - warnings and precautions
- Change to section 2 - interactions with other medicines, food or drink
- Change to section 2 - pregnancy, breast feeding and fertility
- Change to section 3 - how to take/use
- Change to section 3 - overdose, missed or forgotten doses
- Change to section 4 - possible side effects
- Change to section 6 - date of revision
Updated on 24 April 2018
File name
Adv_SPC_BO_13_0_IE_Clean.docx
Reasons for updating
- Change to section 5.2 - Pharmacokinetic properties
Legal category:Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
The SPC has been updated as follows: spc section 5.2 subsections distribution and elimination updated for the absolute PK value derived from study 1044:
Updated on 16 February 2018
Reasons for updating
- New SPC for new product
Legal category:Product subject to medical prescription which may not be renewed (A)
Updated on 16 February 2018
Reasons for updating
- Change to section 4.8 - Undesirable effects
- Change to section 5.3 - Preclinical safety data
Legal category:Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
The following changes to the labelling have been approved. Please refer to attached copy/copies of labelling documentation for full details.
|
The SPC has been updated as follows: section 4.8 and 5.3 to make editorial changes |
Updated on 14 February 2018
File name
PIL_15807_880.pdf
Reasons for updating
- New PIL for new product
Updated on 14 February 2018
Reasons for updating
- Change to section 4.8 - Undesirable effects
- Change to section 5.3 - Preclinical safety data
- SPC submitted in error
Legal category:Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
The following changes to the labelling have been approved. Please refer to attached copy/copies of labelling documentation for full details.
|
The SPC has been updated as follows: to make editorial changes to section 4.8 and 5.3 |
Updated on 14 February 2018
Reasons for updating
- Change to section 4 - how to report a side effect
- Change to section 6 - what the product looks like and pack contents
- Change to section 6 - date of revision
Updated on 13 February 2018
Reasons for updating
- Change to section 4 - how to report a side effect
- Change to section 6 - what the product looks like and pack contents
- Change to section 6 - date of revision
- Submitted in error
Updated on 27 April 2017
Reasons for updating
- Change to section 4.1 - Therapeutic indications
- Change to section 4.2 - Posology and method of administration
- Change to section 4.3 - Contraindications
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
- Change to section 4.8 - Undesirable effects
- Change to section 5.1 - Pharmacodynamic properties
- Change to section 5.2 - Pharmacokinetic properties
- Change to section 5.3 - Preclinical safety data
- Change to section 6.1 - List of excipients
- Change to section 6.5 - Nature and contents of container
- Change to section 8 - Marketing authorisation number(s)
- Change to section 9 - Date of first authorisation/renewal of the authorisation
- Change to section 10 - Date of revision of the text
Legal category:Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
|
The SPC has been updated as follows: Minor stylistic changes in section 4.1-4.5, 4.8, 5.1-5.3, 6.1, 6.5, 8, 9 & 10 |
Updated on 21 April 2017
Reasons for updating
- Change to section 2 - interactions with other medicines, food or drink
- Change to section 4 - possible side effects
- Change to section 6 - what the product contains
- Change to section 6 - date of revision
Updated on 04 April 2017
Reasons for updating
- Change to section 4.1 - Therapeutic indications
- Change to section 4.2 - Posology and method of administration
- Change to section 4.3 - Contraindications
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
- Change to section 4.8 - Undesirable effects
- Change to section 5.1 - Pharmacodynamic properties
- Change to section 5.2 - Pharmacokinetic properties
- Change to section 5.3 - Preclinical safety data
- Change to section 6.1 - List of excipients
- Change to section 6.5 - Nature and contents of container
- Change to section 8 - Marketing authorisation number(s)
- Change to section 9 - Date of first authorisation/renewal of the authorisation
- Change to section 10 - Date of revision of the text
Legal category:Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
Updated on 03 April 2017
Reasons for updating
- Change to section 2 - interactions with other medicines, food or drink
- Change to section 4 - possible side effects
- Change to section 6 - what the product contains
- Change to section 6 - date of revision
Updated on 15 December 2016
Reasons for updating
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.8 - Undesirable effects
Legal category:Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
Updated on 14 December 2016
Reasons for updating
- Change to section 2 - what you need to know - warnings and precautions
- Change to section 4 - possible side effects
- Change to section 6 - date of revision
Updated on 08 July 2016
Reasons for updating
- Change to section 10 - Date of revision of the text
Legal category:Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
the update to the SPC and PIL to what was previously issued is the date of revision and regulatory reference number.
Date of revision updated from 04/2016 to 05/2016 to reflect the date EMA accepted the Type IA notification and as advise by Above country regulatoryUpdated on 06 July 2016
Reasons for updating
- Change to date of revision
Updated on 11 May 2016
Reasons for updating
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.8 - Undesirable effects
Legal category:Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
The SPC has been updated as follows:
Sections 4.4 and 4.8 - Addition of Hepatitis B reactivationUpdated on 06 May 2016
Reasons for updating
- Change to warnings or special precautions for use
- Change to side-effects
- Change to date of revision
Updated on 01 December 2015
Reasons for updating
- Change to section 4.8 - Undesirable effects
Legal category:Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
The SPC has been updated as follows:
Section 4.8 - Addition of the Adverse reaction – hypertensionUpdated on 26 November 2015
Reasons for updating
- Change to side-effects
- Change to date of revision
Updated on 19 November 2015
Reasons for updating
- Change to section 5.2 - Pharmacokinetic properties
Legal category:Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
The SPC has been updated as follows:
5.2 Pharmacokinetic properties
- Update the Pharmacokinetic properties information after analysis of final study report for study B1871044 in fulfilment of MEA 005.2
Updated on 18 August 2015
Reasons for updating
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
- Change to Section 4.8 – Undesirable effects - how to report a side effect
- Change to section 5.1 - Pharmacodynamic properties
Legal category:Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
The SPC has been updated as follows
Section 4.4:
Replacement of the word ‘ potent’ with ‘strong’ within this section.
Section 4.5 :
CYP3A inhibitors – text updated( please refer to tracked SPC to view changes)
CYP3A inducers – text updated ( please refer to tracked SPC to view changes)
Effects of bosutinib on other medicinal products - text updated ( please refer to tracked SPC to view changes)
Section 4.8
Update from IMB to HPRA
Section 5.1
Minor editing changes
Updated on 17 August 2015
Reasons for updating
- Change to side-effects
- Change to drug interactions
- Change to further information section
- Change to date of revision
Updated on 12 January 2015
Reasons for updating
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
- Change to section 6.3 - Shelf life
Legal category:Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
The SPC has been updated as follows:
Section 6.3 – Shelf life update to 4 years.
Section 4.5 – paragraph ‘ Proton pump inhibitors’ - spelling correction ‘ bosutinib’
Updated on 24 November 2014
Reasons for updating
- Change to section 4.4 - Special warnings and precautions for use
Legal category:Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
Updated on 05 August 2014
Reasons for updating
- Improved electronic presentation
Updated on 08 July 2014
Reasons for updating
- Change to section 4.2 - Posology and method of administration
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 5.2 - Pharmacokinetic properties
- Change to section 6.5 - Nature and contents of container
- Change to section 8 - MA number
Legal category:Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
Updates to Sections 4.2, 4.4, 5.2, 6.5 & 8
Updated on 04 July 2014
Reasons for updating
- Change to date of revision
- Change to dosage and administration
- Introduction of new pack/pack size
Updated on 05 March 2014
Reasons for updating
- Addition of black triangle
- Change to section 4.8 - Undesirable effects
Legal category:Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
Update to section 4.8
Updated on 27 February 2014
Reasons for updating
- Change to side-effects
- Change to date of revision
Updated on 01 August 2013
Reasons for updating
- New SPC for new product
Legal category:Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
Updated on 01 August 2013
Reasons for updating
- New PIL for new product
Pfizer Healthcare Ireland Unlimited Company
Address:
The Watermarque Building, Ringsend Road, Dublin 4, D04 K7N3, IrelandTelephone:
+353 1 467 6500Fax:
+353 1 467 6501Website:
https://www.pfizermedicalinformation.ie/Medical Information Direct Line:
1 800 633 363